ReCare: 500 patients enrolled

We are pleased to announce that on 23 May 2025, the RP-2011 ReCare cohort of the 1811-E²-RADIatE platform successfully enrolled its 500th patient, a significant milestone for the cohort launched in May 2023. This achievement marks the completion of the first phase of recruitment.

We are also glad to share that regulatory submissions for 2011 ReCare v3.0 have been initiated. This updated version expands the eligible tumour types to include head and neck (H&N) and brain tumours. We are currently awaiting feedback from the relevant authorities and will notify and activate participating sites upon regulatory approval.

Moreover, Jonas Willmann, one of the ReCare cohort study coordinators, presented the first early pattern-of-care analysis at ESTRO 2025 in Vienna, Austria, based on data from the initial patients enrolled in the ESTRO/EORTC E²-RADIatE ReCare cohort.

We extend our heartfelt thanks to all investigators and their teams for their invaluable contributions. Most importantly, we are deeply grateful to our patients, whose participation makes milestones like this possible.

Thank you for your continued support!